OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, et al.
Annals of Oncology (2020) Vol. 31, Iss. 3, pp. 334-351
Open Access | Times Cited: 188
L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, et al.
Annals of Oncology (2020) Vol. 31, Iss. 3, pp. 334-351
Open Access | Times Cited: 188
Showing 1-25 of 188 citing articles:
Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1290
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1290
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
Zhenwei Peng, Wenzhe Fan, Bowen Zhu, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 1, pp. 117-127
Closed Access | Times Cited: 286
Zhenwei Peng, Wenzhe Fan, Bowen Zhu, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 1, pp. 117-127
Closed Access | Times Cited: 286
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, et al.
Nature Cancer (2022) Vol. 3, Iss. 4, pp. 386-401
Open Access | Times Cited: 270
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, et al.
Nature Cancer (2022) Vol. 3, Iss. 4, pp. 386-401
Open Access | Times Cited: 270
Changing epidemiology of hepatocellular carcinoma in Asia
Chenhao Zhang, Yifei Cheng, Shu Zhang, et al.
Liver International (2022) Vol. 42, Iss. 9, pp. 2029-2041
Closed Access | Times Cited: 236
Chenhao Zhang, Yifei Cheng, Shu Zhang, et al.
Liver International (2022) Vol. 42, Iss. 9, pp. 2029-2041
Closed Access | Times Cited: 236
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)
Ning Lyu, Xun Wang, Jibin Li, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 5, pp. 468-480
Closed Access | Times Cited: 205
Ning Lyu, Xun Wang, Jibin Li, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 5, pp. 468-480
Closed Access | Times Cited: 205
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapyversuslenvatinib alone for advanced hepatocellular carcinoma
Minke He, Run-Bin Liang, Yang Zhao, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 150
Minke He, Run-Bin Liang, Yang Zhao, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 150
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update
Ningyuan Wen, Yulong Cai, Fu‐Yu Li, et al.
BioScience Trends (2022) Vol. 16, Iss. 1, pp. 20-30
Open Access | Times Cited: 136
Ningyuan Wen, Yulong Cai, Fu‐Yu Li, et al.
BioScience Trends (2022) Vol. 16, Iss. 1, pp. 20-30
Open Access | Times Cited: 136
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Shukui Qin, Masatoshi Kudo, Tim Meyer, et al.
JAMA Oncology (2023) Vol. 9, Iss. 12, pp. 1651-1651
Open Access | Times Cited: 106
Shukui Qin, Masatoshi Kudo, Tim Meyer, et al.
JAMA Oncology (2023) Vol. 9, Iss. 12, pp. 1651-1651
Open Access | Times Cited: 106
Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1
Hao Cai, Yichi Zhang, Jian Wang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 91
Hao Cai, Yichi Zhang, Jian Wang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 91
Immune-Based Combinations for Advanced Hepatocellular Carcinoma: Shaping the Direction of First-Line Therapy
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Future Oncology (2021) Vol. 17, Iss. 7, pp. 755-757
Closed Access | Times Cited: 84
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Future Oncology (2021) Vol. 17, Iss. 7, pp. 755-757
Closed Access | Times Cited: 84
Treatment and the prognosis of hepatocellular carcinoma in Asia
Takuji Torimura, Hideki Iwamoto
Liver International (2021) Vol. 42, Iss. 9, pp. 2042-2054
Open Access | Times Cited: 83
Takuji Torimura, Hideki Iwamoto
Liver International (2021) Vol. 42, Iss. 9, pp. 2042-2054
Open Access | Times Cited: 83
Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
Kunpeng Wang, Cong Wang, Hao Jiang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 62
Kunpeng Wang, Cong Wang, Hao Jiang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 62
CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle
Yugang Huang, Dan Li, Li Wang, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 39
Yugang Huang, Dan Li, Li Wang, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 39
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Ming Zhao, Zhi Guo, Yinghua Zou, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 4-31
Closed Access | Times Cited: 23
Ming Zhao, Zhi Guo, Yinghua Zou, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 4-31
Closed Access | Times Cited: 23
Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitiors for unresectable hepatocellular carcinoma and meta-analysis
Yu-Zhe Cao, Guang-lei Zheng, Tianqi Zhang, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 4, pp. 318-331
Open Access | Times Cited: 9
Yu-Zhe Cao, Guang-lei Zheng, Tianqi Zhang, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 4, pp. 318-331
Open Access | Times Cited: 9
Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Valerie Chew, Chien-Huai Chuang, Chiun Hsu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 8
Valerie Chew, Chien-Huai Chuang, Chiun Hsu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 8
Primary Hepatocellular Carcinosarcoma: A Case Series and Literature Review
Hailong Qiao, Huaibin Guo, Ze Liang, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102520-102520
Closed Access | Times Cited: 1
Hailong Qiao, Huaibin Guo, Ze Liang, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102520-102520
Closed Access | Times Cited: 1
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang, et al.
Liver Cancer (2020) Vol. 9, Iss. 5, pp. 613-624
Open Access | Times Cited: 50
Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang, et al.
Liver Cancer (2020) Vol. 9, Iss. 5, pp. 613-624
Open Access | Times Cited: 50
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Takuji Torimura, Hideki Iwamoto
Clinical and Molecular Hepatology (2020) Vol. 27, Iss. 2, pp. 236-245
Open Access | Times Cited: 50
Takuji Torimura, Hideki Iwamoto
Clinical and Molecular Hepatology (2020) Vol. 27, Iss. 2, pp. 236-245
Open Access | Times Cited: 50
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD
Masafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, et al.
Liver Cancer (2023) Vol. 13, Iss. 2, pp. 193-202
Open Access | Times Cited: 21
Masafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, et al.
Liver Cancer (2023) Vol. 13, Iss. 2, pp. 193-202
Open Access | Times Cited: 21
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung‐Hung Su, Chih‐Horng Wu, Tsung‐Hao Liu, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 230-241
Open Access | Times Cited: 20
Tung‐Hung Su, Chih‐Horng Wu, Tsung‐Hao Liu, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 230-241
Open Access | Times Cited: 20
Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation
Xiaoli Liao, Junming Chen, DongCheng Luo, et al.
Pathology & Oncology Research (2023) Vol. 28
Open Access | Times Cited: 19
Xiaoli Liao, Junming Chen, DongCheng Luo, et al.
Pathology & Oncology Research (2023) Vol. 28
Open Access | Times Cited: 19
Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis
John Leung, Shyh-Yau Wang, Henry W. C. Leung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
John Leung, Shyh-Yau Wang, Henry W. C. Leung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Cell-free DNA testing for early hepatocellular carcinoma surveillance
Lei Chen, Tong Wu, Rong Fan, et al.
EBioMedicine (2024) Vol. 100, pp. 104962-104962
Open Access | Times Cited: 6
Lei Chen, Tong Wu, Rong Fan, et al.
EBioMedicine (2024) Vol. 100, pp. 104962-104962
Open Access | Times Cited: 6
Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial
Yi Lin, G. Wu, Ming Yue Rao, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Yi Lin, G. Wu, Ming Yue Rao, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
